Our results suggest that the blockade of IL-6 receptor by sarilumab improves the hemoglobin level, possibly via decreasing hepcidin levels, and may contribute to the greater improvement in anemia observed with IL-6 inhibitors [34]. This evidence concerns the gene IL6 and anemia.